Abstract Library

#2236 Carcinoid Syndrome Open Questions – Evaluations from a Real Life Setting

Introduction: Carcinoid syndrome (CS) is frequent in patients with neuroendocrine neoplasia of the small bowel and limits quality of life and may influence prognosis compared to patients with non-functional neuroendocrine neoplasia.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Fijalkowski R, Singh A, Baum R, Kulkarni H, Niepsch K,

Keywords: carcinoid syndrome, neuroendocrine,

#1944 Predictive Value of Baseline Hematology Parameters on Outcome of 177Lu-DOTATOC PRRT

Introduction: In external beam radiotherapy it has been well established that improved tissue O2 increases therapy efficacy, likely mediated by O2 derived free radicals. Additionally, emerging evidence suggests immuno-stimulatory effects of radiotherapy through activation of lymphocytes.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kluge A

Authors: Kluge A, Baum R, Kulkarni H, Niepsch K, Bitterlich N,

Keywords: PRRT, hematology, prognosis, 177Lu-DOTATOC,

#1570 Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years

Introduction: Peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR) expressing neuroendocrine neoplasms (NEN) has shown promising results about progression free survival (PFS) and overall survival (OS) in numerous phase II trials, and also in a recently published randomized controlled prospective phase III study (NETTER-1).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Niepsch K, Kaemmerer D, Hommann M,

Keywords: PRRT, Survival, PET/CT,

#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center

Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Zachert C, Kaemmerer D, Petrovitch A,

Keywords: PRRT,

#781 Effect of Mean Absorbed Renal Dose on the Renal Function After Peptide Receptor Radionuclide Therapy

Introduction: Kidneys are the critical organs in peptide receptor radionuclide therapy (PRRNT) of neuroendocrine neoplasms (NENs).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Kulkarni H, Schuchardt C, Wiessalla S, Senftleben S, Baum R,

Keywords: mean absorbed renal dose, renal toxicity, peptide receptor radionuclide therapy,